Vericel (VCEL) said Wednesday it has received approval for the commercial manufacturing of autologous cultured chondrocytes on porcine collagen membrane, or MACI, as its Massachusetts facility from the US Food and Drug Administration.
The approval allows Vericel to start commercial production of the knee cartilage repair product at the facility in Burlington in Q2, allowing it to meet increasing demand, the company said.